P
Paul Nathan
Researcher at Northwood University
Publications - 213
Citations - 17048
Paul Nathan is an academic researcher from Northwood University. The author has contributed to research in topics: Melanoma & Trametinib. The author has an hindex of 44, co-authored 181 publications receiving 13804 citations. Previous affiliations of Paul Nathan include John Radcliffe Hospital & Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James L. Alexander,Hajir Ibraheim,Bhavisha Sheth,Jessica Little,Muhammad Saheb Khan,Camellia Richards,Nikki Hunter,Dharmisha Chauhan,Raguprakash Ratnakumaran,Kathleen Mchugh,David J. Pinato,Paul Nathan,Julia Choy,Shanthini M Crusz,Andrew Furness,Samra Turajlic,Lisa Pickering,James Larkin,Julian Teare,Sophie Papa,Sophie Papa,Ally Speight,Anand Sharma,Nick Powell +23 more
TL;DR: In this paper, the authors conducted a multicenter (six cancer centers), cohort study of outcomes in patients treated with IFX for corticosteroid-refractory CPI-induced enterocolitis between 2007 and 2020.
Journal ArticleDOI
Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.
Jean-Jacques Grob,Keith T. Flaherty,Georgina V. Long,Paul Nathan,Dirk Schadendorf,Antoni Ribas,Caroline Robert,Stephen R. Lane,Carmen Mak,Philippe Legenne,Michael A. Davies +10 more
TL;DR: D+T trials of D+T have provided a large homogeneous dataset for evaluating these agents in p competition, and these agents have shown promising results in Phase 2 and phase 3.
Journal ArticleDOI
Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).
Jessica Yang,Marlana Orloff,Joseph J. Sacco,Leonel Hernandez-Aya,Karla A. Lee,Sophie Merrick,Paul Nathan,Samuel Pan,Jose Lutzky,Mark R. Middleton,Alexandra Nesson,Shahnaz V. Singh-Kandah,Susana Hernandez,Takami Sato,Richard D. Carvajal +14 more
TL;DR: IMC is a bispecific agent composed of a high affinity T cell receptor targeting the T cell receptors in response to anti-CTLA4/PD1 monotherapy and shows good specificity for T cell reprograming.
Journal ArticleDOI
UK guidelines for the systemic treatment of renal cell carcinoma
TL;DR: UK consensus guidelines on the use of systemic therapies for patients with advanced renal cell carcinoma are presented.
Journal ArticleDOI
A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM).
Paul Nathan,Ernest Marshall,Catrin Tudur Smith,Matthew Bickerstaff,Carles Escriu,Maria Marples,Bertil Damato,Helen Kalirai,Sarah E. Coupland +8 more
TL;DR: A large number of patients diagnosed with metastatic uveal melanoma with atypical prognosis are likely to have progressed after initial treatment with chemotherapy or radiation, and the prognosis for these patients is poor.